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Background
Asthma is the most common serious chronic lung disease
that affects people of all ages with evidence for a growing
prevalence in industrialized as well as in developing coun-
tries. Allergic asthma is considered to be a Th2-dominant
chronic inflammatory disease of the lungs. Th2 cells secret
a panel of cytokines with several overlapping functions
including IL-4, IL-5, IL-13, and GM-CSF. Increased Th2-
cytokine and IgE levels and accumulation activation of
Th2 cells, eosinophils and mast cells are observed in asth-
matic lungs. However, recent studies focused on cell-
based mechanisms for the pathogenesis of allergic asthma.
Methods
In this study we compare the anti-IgE treatment modality
in the dynamics of immune system cytokine levels of IL-8,
IL-17, TGF-beta and GSCF in asthma patients who had
no other any allergic disease, newly diagnosed allergic
asthma patients and healthy volunteers.
Results
The study population consisted of 14 patients suffering of
SPA, 14 newly diagnosed allergic asthma patients and 14
healthy volunteers included as controls. Plasma levels of
cytokines were measured. Total and specific IgE levels of
anti-IgE monoclonal antibody treated patients, serum
high-sensitivity C-reactive protein levels, FEV1/FVC rates
and asthma control test (ACT) were measured for the
clinical follow-up.
Conclusions
We observed that patients who had SPA whom were trea-
ted with anti-IgE monoclonal antibody presented increas-
ing levels of IL-8, TGF-b and GCSF during the treatment
period of sampling times at 4 months and 18 months.
However this increase was not correlated neither with
serum hsCRP levels nor FEV1/FVC rates. We also noted
that the levels of these cytokines did not differ between
newly diagnosed allergic asthma patients, non-treated
asthma patients and control.
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